To include your compound in the COVID-19 Resource Center, submit it here.

FDA grants Priority Review to GW's Epidiolex for seizures

GW Pharmaceuticals plc (NASDAQ:GWPH) said FDA accepted and granted Priority Review to an NDA for Epidiolex cannabidiol as an

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE